Department of Clinical Pharmacy and Translational Science, College of Pharmacy, University of Tennessee Health Sciences Center, Memphis, Tennessee, USA.
Department of Clinical Pharmacy and Translational Science, College of Pharmacy, University of Tennessee Health Sciences Center, Memphis, Tennessee, USA
Antimicrob Agents Chemother. 2018 Dec 21;63(1). doi: 10.1128/AAC.01337-18. Print 2019 Jan.
Increased expression of drug efflux pumps and changes in the target enzyme Erg11p are known to contribute to azole resistance in , one of the most prevalent fungal pathogens. Mutations that inactivate , which encodes sterol Δ-desaturase, also confer azole resistance. However, it is unclear whether the loss of Erg3p activity is sufficient to confer resistance within the mammalian host, and relatively few mutants have been reported among azole-resistant clinical isolates. Trailing growth (residual growth in the presence of the azoles) is a phenotype observed with many isolates and, in its extreme form, can be mistaken for resistance. The purpose of this study was to determine whether the growth of Erg3p-deficient mutants in the presence of the azoles possesses the characteristics of azole resistance or of an exaggerated form of trailing growth. Our results demonstrate that, similar to trailing isolates, the capacity of an Δ/Δ mutant to endure the consequences of azole exposure is at least partly dependent on both temperature and pH. This contrasts with true azole resistance that results from enhanced drug efflux and/or changes in the target enzyme. The Δ/Δ mutant and trailing isolates also appear to sustain significant membrane damage upon azole treatment, further distinguishing them from resistant isolates. However, the insensitivity of the Δ/Δ mutant to azoles is unaffected by the calcineurin inhibitor cyclosporin A, distinguishing it from trailing isolates. In conclusion, the mutant phenotype is qualitatively and quantitatively distinct from both azole resistance and trailing growth.
已知药物外排泵的表达增加和靶酶 Erg11p 的变化导致真菌病原体中最常见的之一对唑类药物产生耐药性。失活编码甾醇 Δ-去饱和酶的突变也赋予对唑类药物的耐药性。然而,尚不清楚 Erg3p 活性的丧失是否足以在哺乳动物宿主中赋予耐药性,并且在唑类耐药的临床分离株中报道的相对较少。尾随生长(唑类药物存在下的残留生长)是许多观察到的 分离株的表型,在其极端形式下,可能被误认为是耐药性。本研究的目的是确定唑类药物存在下 Erg3p 缺陷的 突变体的生长是否具有唑类耐药性或过度形式的尾随生长的特征。我们的结果表明,与尾随分离株相似,Δ/Δ 突变体在唑类暴露后耐受其后果的能力至少部分取决于温度和 pH 值。这与增强药物外排和/或靶酶变化导致的真正唑类耐药性形成对比。Δ/Δ 突变体和尾随分离株在唑类药物处理后似乎也会持续受到显著的膜损伤,这进一步将它们与耐药分离株区分开来。然而,Δ/Δ 突变体对唑类药物的不敏感性不受钙调神经磷酸酶抑制剂环孢素 A 的影响,这将其与尾随分离株区分开来。总之,Δ/Δ 突变体表型在质和量上都与唑类耐药性和尾随生长明显不同。